AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
FALK THOMAS J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Thomas J. Falk reported a compensation-related equity grant. He received 1,118 shares of AbbVie common stock at $0.00 per share as a grant of restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. Following this award, he holds 2,321 AbbVie shares directly. The restricted stock units will be settled one-for-one in AbbVie shares upon the earlier of his separation from service, death, or a change in control as defined in the program. Separately, an additional 3,000 shares are owned indirectly through a limited partnership jointly controlled by Falk and his spouse, for which he disclaims beneficial ownership except for his pecuniary interest.
WADDELL FREDERICK H reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Frederick H. Waddell received an equity grant of 1,118 shares of AbbVie common stock in the form of restricted stock units. The award was granted at no cash cost to him as part of AbbVie’s incentive stock program.
The restricted stock units will be settled on a one-to-one basis in AbbVie shares upon the earlier of his separation from service, death, or a change in control as defined in the program. Following this grant, he directly holds 30,076 AbbVie shares.
Roberts Rebecca B reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Rebecca B. Roberts received a grant of 1,118 shares of common stock in the form of restricted stock units. These units were awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program and carry a zero-dollar grant price. After this grant, she directly holds 14,846 shares. The units will be settled on a one‑for‑one basis in AbbVie common stock upon the earlier of her separation from service, death, or a change in control as defined in the program.
AbbVie Inc. director Edward J. Rapp received an award of 1,118 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. Each unit will convert into one share of AbbVie common stock on the earlier of his separation from service, death, or a change in control as defined in the program. Following this grant, Rapp holds 45,964 AbbVie shares directly, including 10,388 shares previously held indirectly through a spouse’s trust that are now held directly.
Quaggin Susan E reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Susan E. Quaggin received an award of 1,118 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. The units will be settled in an equal number of AbbVie common shares upon the earlier of her separation from service, death, or a change in control as defined in the program.
Following this grant, she directly holds 3,643 shares of AbbVie common stock.
MEYER MELODY B reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Melody B. Meyer received an award of 1,118 shares of common stock in the form of restricted stock units. These units were granted at no cash cost to her and increase her directly owned holdings to 17,616 shares.
The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be settled on a one-to-one basis in AbbVie common stock upon the earlier of her separation from service, death, or a change in control as defined in the program.
Hart Brett J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Brett J. Hart received an award of 1,118 shares of common stock in the form of restricted stock units. These units were granted at no cash cost to him and increase his direct holdings to 20,590 shares after the award.
The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be settled one-for-one in AbbVie common stock. Settlement will occur on the earlier of his separation from service, death, or a change in control as defined in the program.
FREYMAN THOMAS C reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Thomas C. Freyman received a grant of 1,118 restricted stock units of AbbVie common stock at a stated price of $0.00 per share. After this award, he directly holds 127,869 shares of AbbVie common stock.
The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be paid one-for-one in AbbVie shares upon the earlier of his separation from service, death, or a defined change in control. Additional AbbVie shares are held in trusts for his spouse and son, totaling 1,941 shares and 4,000 shares respectively, for which he disclaims beneficial ownership.
AbbVie Inc. director Jennifer L. Davis received an equity-based compensation award rather than buying shares on the market. She was granted 1,118 restricted stock units under AbbVie’s Amended and Restated 2013 Incentive Stock Program, increasing her reported direct holdings to 3,643 common shares. These units will convert into AbbVie stock on a one-to-one basis upon her separation from service, death, or a qualifying change in control, aligning her compensation more closely with long-term shareholder value.
BURNSIDE WILLIAM H.L. reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director William H.L. Burnside received a grant of 1,118 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. These units will be settled one-for-one in AbbVie common stock upon the earlier of separation from service, death, or a change in control, bringing his reported holdings to 28,076 shares.